HomeMOLN • SWX
add
Molecular Partners AG
Previous close
CHF 3.26
Day range
CHF 3.16 - CHF 3.32
Year range
CHF 2.70 - CHF 9.50
Market cap
130.45M CHF
Avg Volume
28.72K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Financials
Income Statement
Revenue
Net income
| (CHF) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 16.14M | 259.35% |
Net income | -16.77M | -48.09% |
Net profit margin | — | — |
Earnings per share | -0.45 | — |
EBITDA | -15.59M | -2.21% |
Effective tax rate | 0.01% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 130.91M | -24.82% |
Total assets | 141.10M | -23.98% |
Total liabilities | 12.90M | -24.36% |
Total equity | 128.19M | — |
Shares outstanding | 37.27M | — |
Price to book | 0.95 | — |
Return on assets | -26.94% | — |
Return on capital | -29.41% | — |
Cash Flow
Net change in cash
| (CHF) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -16.77M | -48.09% |
Cash from operations | -17.08M | -0.18% |
Cash from investing | 34.96M | 98.53% |
Cash from financing | -302.00K | -0.67% |
Net change in cash | 17.50M | 1,588.90% |
Free cash flow | -13.72M | -22.38% |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
159
